Specifically, we focus on the different types of therapeutic agents that can inhibit the NLRP3 inflammasome and summarize their pharmacological effectiveness for NAFLD treatment. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.